245 related articles for article (PubMed ID: 35203791)
1. Assessment of In Vitro Cefiderocol Susceptibility and Comparators against an Epidemiologically Diverse Collection of
Ballesté-Delpierre C; Ramírez Á; Muñoz L; Longshaw C; Roca I; Vila J
Antibiotics (Basel); 2022 Jan; 11(2):. PubMed ID: 35203791
[TBL] [Abstract][Full Text] [Related]
2. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
Delgado-Valverde M; Conejo MDC; Serrano L; Fernández-Cuenca F; Pascual Á
J Antimicrob Chemother; 2020 Jul; 75(7):1840-1849. PubMed ID: 32277821
[TBL] [Abstract][Full Text] [Related]
3. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
4. Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives?
Le Terrier C; Freire S; Nordmann P; Poirel L
Eur J Clin Microbiol Infect Dis; 2024 Feb; 43(2):339-354. PubMed ID: 38095831
[TBL] [Abstract][Full Text] [Related]
5. In Vitro Activity of Cefiderocol against a Global Collection of Carbapenem-Resistant
Seifert H; Müller C; Stefanik D; Higgins PG; Wohlfarth E; Kresken M
Antibiotics (Basel); 2023 Jul; 12(7):. PubMed ID: 37508268
[No Abstract] [Full Text] [Related]
6. In vitro activity of cefiderocol and comparators against isolates of Gram-negative bacterial pathogens from a range of infection sources: SIDERO‑WT‑2014-2018 studies in Spain.
Cercenado E; Cardenoso L; Penin R; Longshaw C; Henriksen AS; Pascual A
J Glob Antimicrob Resist; 2021 Sep; 26():292-300. PubMed ID: 34274538
[TBL] [Abstract][Full Text] [Related]
7. In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan.
Hsueh SC; Lee YJ; Huang YT; Liao CH; Tsuji M; Hsueh PR
J Antimicrob Chemother; 2019 Feb; 74(2):380-386. PubMed ID: 30357343
[TBL] [Abstract][Full Text] [Related]
8. Cefiderocol Antimicrobial Susceptibility Testing Considerations: the Achilles' Heel of the Trojan Horse?
Simner PJ; Patel R
J Clin Microbiol; 2020 Dec; 59(1):. PubMed ID: 32727829
[TBL] [Abstract][Full Text] [Related]
9. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.
Falagas ME; Skalidis T; Vardakas KZ; Legakis NJ;
J Antimicrob Chemother; 2017 Jun; 72(6):1704-1708. PubMed ID: 28369471
[TBL] [Abstract][Full Text] [Related]
10.
Hackel MA; Tsuji M; Yamano Y; Echols R; Karlowsky JA; Sahm DF
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29158270
[TBL] [Abstract][Full Text] [Related]
11.
Longshaw C; Manissero D; Tsuji M; Echols R; Yamano Y
JAC Antimicrob Resist; 2020 Sep; 2(3):dlaa060. PubMed ID: 34223017
[TBL] [Abstract][Full Text] [Related]
12. In vitro antibacterial activity of cefiderocol against recent multidrug-resistant carbapenem-nonsusceptible Enterobacterales isolates.
Zhang Q; Neidig N; Chu TY; Divoky C; Carpenter J; Lee-Hsiao C; Threatt H; Sultana R; Bush K
Diagn Microbiol Infect Dis; 2022 May; 103(1):115651. PubMed ID: 35228130
[TBL] [Abstract][Full Text] [Related]
13. Activity of Cefiderocol Against
Iregui A; Khan Z; Landman D; Quale J
Microb Drug Resist; 2020 Jul; 26(7):722-726. PubMed ID: 32031915
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of cefiderocol and comparators against Gram-negative bacterial isolates from a series of surveillance studies in England: 2014-2018.
Gant V; Hussain A; Bain M; Longshaw C; Henriksen AS
J Glob Antimicrob Resist; 2021 Dec; 27():1-11. PubMed ID: 34329792
[TBL] [Abstract][Full Text] [Related]
15. In Vitro Antimicrobial Activity of the Siderophore Cephalosporin Cefiderocol against
Carcione D; Siracusa C; Sulejmani A; Migliavacca R; Mercato A; Piazza A; Principe L; Clementi N; Mancini N; Leoni V; Intra J
Antibiotics (Basel); 2021 Oct; 10(11):. PubMed ID: 34827247
[TBL] [Abstract][Full Text] [Related]
16.
Hackel MA; Tsuji M; Yamano Y; Echols R; Karlowsky JA; Sahm DF
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630181
[TBL] [Abstract][Full Text] [Related]
17.
Mushtaq S; Sadouki Z; Vickers A; Livermore DM; Woodford N
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32958717
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility of cefiderocol and other antibiotics against carbapenem-resistant, Gram-negative bacteria.
Wang Y; Li Y; Zhao J; Guan J; Ni W; Gao Z
Ann Transl Med; 2022 Mar; 10(5):261. PubMed ID: 35402576
[TBL] [Abstract][Full Text] [Related]
19. In vivo efficacy & resistance prevention of cefiderocol in combination with ceftazidime/avibactam, ampicillin/sulbactam or meropenem using human-simulated regimens versus Acinetobacter baumannii.
Gill CM; Santini D; Takemura M; Longshaw C; Yamano Y; Echols R; Nicolau DP
J Antimicrob Chemother; 2023 Apr; 78(4):983-990. PubMed ID: 36775993
[TBL] [Abstract][Full Text] [Related]
20. Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens.
Dobias J; Dénervaud-Tendon V; Poirel L; Nordmann P
Eur J Clin Microbiol Infect Dis; 2017 Dec; 36(12):2319-2327. PubMed ID: 28748397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
